Executive SummaryBoulder, Colo.-based biotech firm's annual report for 1987 notes plan to put angiogenesis factor in clinical trials for wound healing in second half of 1988. Also approaching the clinic is the firm's elastase inhibitor, a collaborative project between Synergen and Ciba-Geigy.
You may also be interested in...
Podcast: Living In China's Coronavirus Lockdown, Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.